Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Flesinoxan

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Flesinoxan
Clinical data
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • 4-fluoro-N-(2-{4-[(2S)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-5-yl]piperazin-1-yl}ethyl)benzamide
CAS Number
PubChemCID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC22H26FN3O4
Molar mass415.465 g·mol−1
3D model (JSmol)
  • C1CN(CCN1CCNC(=O)C2=CC=C(C=C2)F)C3=C4C(=CC=C3)O[C@H](CO4)CO
  • InChI=1S/C22H26FN3O4/c23-17-6-4-16(5-7-17)22(28)24-8-9-25-10-12-26(13-11-25)19-2-1-3-20-21(19)29-15-18(14-27)30-20/h1-7,18,27H,8-15H2,(H,24,28)/t18-/m0/s1
  • Key:NYSDRDDQELAVKP-SFHVURJKSA-N

Flesinoxan (DU-29,373) is apotent andselective5-HT1A receptorpartial/near-fullagonist of thephenylpiperazine class.[1][2][3] Originally developed as a potentialantihypertensive drug,[1][2][4] flesinoxan was later found to possessantidepressant andanxiolytic effects in animal tests.[5][6] As a result, it was investigated in several smallhumanpilot studies for the treatment ofmajor depressive disorder, and was found to have robusteffectiveness and very goodtolerability.[7][8] However, due to "management decisions", the development of flesinoxan was stopped and it was not pursued any further.[9]

In patients, flesinoxan enhancesREMsleep latency, decreasesbody temperature, and increasesACTH,cortisol,prolactin, andgrowth hormonesecretion.[2][8]

See also

[edit]

References

[edit]
  1. ^abSchoeffter P, Hoyer D (November 1988)."Centrally acting hypotensive agents with affinity for 5-HT1A binding sites inhibit forskolin-stimulated adenylate cyclase activity in calf hippocampus".British Journal of Pharmacology.95 (3):975–85.doi:10.1111/j.1476-5381.1988.tb11728.x.PMC 1854240.PMID 3207999.
  2. ^abcPitchot W, Wauthy J, Legros JJ, Ansseau M (March 2004). "Hormonal and temperature responses to flesinoxan in normal volunteers: an antagonist study".European Neuropsychopharmacology.14 (2):151–5.doi:10.1016/S0924-977X(03)00108-1.PMID 15013031.S2CID 19082134.
  3. ^Hadrava V, Blier P, Dennis T, Ortemann C, de Montigny C (October 1995). "Characterization of 5-hydroxytryptamine1A properties of flesinoxan: in vivo electrophysiology and hypothermia study".Neuropharmacology.34 (10):1311–26.doi:10.1016/0028-3908(95)00098-Q.PMID 8570029.S2CID 27967032.
  4. ^Wouters W, Tulp MT, Bevan P (May 1988). "Flesinoxan lowers blood pressure and heart rate in cats via 5-HT1A receptors".European Journal of Pharmacology.149 (3):213–23.doi:10.1016/0014-2999(88)90651-6.PMID 2842163.
  5. ^van Hest A, van Drimmelen M, Olivier B (1992). "Flesinoxan shows antidepressant activity in a DRL 72-s screen".Psychopharmacology.107 (4):474–9.doi:10.1007/BF02245258.PMID 1351303.S2CID 6258207.
  6. ^Rodgers RJ, Cole JC, Davies A (August 1994). "Antianxiety and behavioral suppressant actions of the novel 5-HT1A receptor agonist, flesinoxan".Pharmacology, Biochemistry, and Behavior.48 (4):959–63.doi:10.1016/0091-3057(94)90205-4.PMID 7972301.S2CID 39446719.
  7. ^Grof P, Joffe R, Kennedy S, Persad E, Syrotiuk J, Bradford D (1993). "An open study of oral flesinoxan, a 5-HT1A receptor agonist, in treatment-resistant depression".International Clinical Psychopharmacology.8 (3):167–72.doi:10.1097/00004850-199300830-00005.PMID 8263314.S2CID 33325915.
  8. ^abAnsseau M, Pitchot W, Moreno AG, Wauthy J, Papart P (2004)."Pilot study of flesinoxan, a 5-HT1A agonist, in major depression: Effects on sleep REM latency and body temperature"(PDF).Human Psychopharmacology: Clinical and Experimental.8 (4):279–283.doi:10.1002/hup.470080407.S2CID 145758823.
  9. ^Celada P, Bortolozzi A, Artigas F (September 2013). "Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research".CNS Drugs.27 (9):703–16.doi:10.1007/s40263-013-0071-0.PMID 23757185.S2CID 31931009.

External links

[edit]
SSRIsTooltip Selective serotonin reuptake inhibitors
SNRIsTooltip Serotonin–norepinephrine reuptake inhibitors
NRIsTooltip Norepinephrine reuptake inhibitors
NDRIsTooltip Norepinephrine–dopamine reuptake inhibitors
NaSSAsTooltip Noradrenergic and specific serotonergic antidepressants
SARIsTooltip Serotonin antagonist and reuptake inhibitors
SMSTooltip Serotonin modulator and stimulators
Others
TCAsTooltip Tricyclic antidepressants
TeCAsTooltip Tetracyclic antidepressants
Others
Non-selective
MAOATooltip Monoamine oxidase A-selective
MAOBTooltip Monoamine oxidase B-selective
Miscellaneous
5-HT1ARTooltip 5-HT1A receptoragonists
GABAARTooltip GABAA receptorPAMsTooltip positive allosteric modulators
Gabapentinoids
(α2δVDCCblockers)
Antidepressants
Sympatholytics
(Antiadrenergics)
Others
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Phenylpiperazines
Benzylpiperazines
Naphthylpiperazines
Quinolinylpiperazines
Diphenylalkylpiperazines
Pyrimidinylpiperazines
Pyridinylpiperazines
Benzo(iso)thiazolylpiperazines
Tricyclic-linked piperazines
Others/uncategorized
Retrieved from "https://en.wikipedia.org/w/index.php?title=Flesinoxan&oldid=1244062880"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp